Precision palliative care for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies a personalized approach to palliative care for people with advanced or recurrent esophageal cancer who are being treated with immunotherapy. It aims to improve quality of life and symptom management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced (stage IV) or recurrent esophageal cancer that has been confirmed by a biopsy.
- You plan to receive treatment with a type of immunotherapy called anti-PD-1 or anti-PD-L1.
- Your overall health should be reasonably good, meaning you are up and about, taking care of yourself, and able to do light activities.
- Your blood counts and organ function (kidney, liver) must be within acceptable ranges.
- You cannot have certain serious medical conditions, such as uncontrolled heart disease, active autoimmune disease, or active infections like hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.